These data suggest that class II mutations induce oncogene addiction to BRAF. In contrast, the cell lines with class III BRAF mutations did not display oncogene addiction to BRAF; knockout of BRAF in these cell lines was no more detrimental than BRAF knockout in other NSCLC cell lines (Fig. 4b). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.